Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug:152:102959.
doi: 10.1016/j.critrevonc.2020.102959. Epub 2020 May 18.

Major and minor salivary gland tumours

Affiliations
Review

Major and minor salivary gland tumours

Gemma Gatta et al. Crit Rev Oncol Hematol. 2020 Aug.

Abstract

Salivary glands carcinomas are very rare epithelial malignant tumors. In 2013 in Europe, 7800 new diagnoses were estimated, 8.5 % of all head and neck cancer. The last WHO classification (2017) counts more than 20 malignant histotypes, this variety as well as the rarity of some of them needs a skilled pathologist for diagnosis. Surgery remains the mainstay of management followed by radiation in high-grade and high-risk pathological features cases. The intensity modulated radiotherapy (IMRT) should be preferred over conformational radiotherapy techniques as adjuvant and exclusive treatment in advanced cases. Particle radiotherapy (i.e. protons, carbon ions) can have a role in advanced/unresectable disease since it was proved to have better results over photons in loco-regional control both in adenoid cystic carcinoma and in other histotypes. Although chemotherapy is still the most frequent treatment for metastatic patients, several new compounds (i.e. anti-angiogenic agents, tailored agents, checkpoint inhibitors) are under investigation.

Keywords: Diagnosis; Epidemiology; Follow up; Molecular targets; Particle radiotherapy; Prognosis; Salivary glands carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest L.D.L. reports grant and other financial relationship with Eisai, Ipsen, Merck Serono, MSD, BMS, Lilly and Biogen; the other authors declare they have no conflict of interest.

LinkOut - more resources